Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508380 | 0.89 | TSHR (0.52) | TP53LTB4R2TSHRMYCPOLB | |
| SCHEMBL1807673 | 0.85 | TSHR (0.43) | TP53LTB4R2TSHRHDAC1HDAC6 | |
| SCHEMBL16508376 | 0.82 | MYC (0.43) | LTB4R2TSHRMYCPOLBALDH1A1 | |
| SCHEMBL28284122 | 0.76 | ADRA2C (0.37) | LTB4R2TSHRPOLBADRA2CALDH1A1 | |
| SCHEMBL1802642 | 0.76 | SLC6A3 (0.41) | TP53TSHRHDAC1HDAC6 | |
| SCHEMBL23748614 | 0.75 | ALDH1A1 (0.44) | TP53TSHRPOLBALDH1A1HPGD | |
| SCHEMBL23748650 | 0.74 | KDM4E (0.41) | TP53TSHRPOLBALDH1A1HPGD | |
| SCHEMBL5515003 | 0.74 | TP53 (0.49) | TP53LTB4R2TSHRALDH1A1 | |
| SCHEMBL9001626 | 0.74 | ADRA2C (0.65) | TP53TSHRPOLBADRA2CALDH1A1 | |
| SCHEMBL1803233 | 0.73 | TSHR (0.54) | TP53LTB4R2TSHRPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464060-B2 | Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-11 | — | — | US | disclosed |
| US-20150057298-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057298-A1 | NOVEL COMPOUNDS | F12, C1R, CHRM1 | TP53 2184/4885LTB4R2 325/4885TSHR 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.